HCM
DNA icon

Highline Capital Management’s Ginkgo Bioworks DNA Stock Holding History

Highline Capital Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-12,500
Closed -$5.79M – 18
2021
Q3 		$5.79M Buy
+12,500
New +$6.08M 4.89% 11

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
SIG
Senator Investment Group New York $2.74B AUM 55.95% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Highline Capital Management's DNA Position: Q4 2021 in Review

Highline Capital Management sold out of Ginkgo Bioworks (DNA) in Q4 2021, closing a stake of 12,500 shares — an estimated $5.79M sold.

Highline Capital Management first reported a position in DNA in Q3 2021 and held it in 1 quarter. The position peaked at $5.79M in Q3 2021. 164 funds tracked by Wall St. Rank hold DNA as of Q4 2021.

  • Highline Capital Management reported no remaining Ginkgo Bioworks position as of Q4 2021 after selling out during the quarter.
  • Highline Capital Management sold 12,500 Ginkgo Bioworks shares in Q4 2021, an estimated $5.79M.
  • Highline Capital Management first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 1 quarter.
  • Highline Capital Management's Ginkgo Bioworks position peaked at $5.79M in Q3 2021.
  • 164 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2021.

Based on Highline Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.